Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Lisinopril Market Poised To Hit $2.47 Billion By 2030 With A 5.5% CAGR
The lisinopril market has experienced substantial growth in recent years. It is anticipated to increase from $1.87 billion in 2025 to $1.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.2%. This historical expansion can be attributed to the rising occurrence of hypertension, the broad clinical acceptance of ACE inhibitors, an expanding aging population, its early integration into heart failure treatment, and enhanced access to primary healthcare.
The lisinopril market is anticipated to experience substantial expansion in the coming years, with its value projected to reach $2.47 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.5%. This anticipated growth during the forecast period is primarily due to factors such as an escalating burden of cardiovascular diseases, an increased need for economical generic medications, a heightened emphasis on preventative cardiac health, wider treatment applications for diabetic kidney disease, and greater healthcare expenditures dedicated to managing chronic conditions. Key trends for the forecast duration involve an increasing incidence of hypertension and cardiovascular ailments, a greater dependence on ACE inhibitors for initial treatment approaches, a surge in generic lisinopril prescriptions, its expanded application in post-heart attack care, and improved patient adherence to long-term chronic care regimens.
Get A Free Sample Report With In-Depth Market Insights:
Lisinopril Market Growth Factors Behind Sustained Expansion
The increasing incidence of cardiovascular diseases is anticipated to fuel the expansion of the lisinopril market. These conditions, known as CVDs, involve various disorders impacting the heart and blood vessels. The rising occurrence of cardiovascular diseases stems from factors such as demographic shifts, an aging populace, various risk factors, and insufficient application of established prevention and treatment protocols. Lisinopril aids in the management of cardiovascular ailments chiefly by reducing blood pressure and alleviating stress on the heart and kidneys. This medication works by hindering angiotensin II production, encouraging blood vessel dilation, diminishing blood volume, and safeguarding organs from damage. As an illustration, the Singapore Heart Foundation (SHF), a non-profit organization based in Singapore, reported that ischemic heart diseases caused 5,302 fatalities in May 2024, a slight increase from 5,290 deaths recorded in 2022. Consequently, the rising prevalence of cardiovascular diseases is a significant impetus for the lisinopril market’s growth.
Lisinopril Market Segment Breakdown: Which Categories Lead On Revenue?
The lisinopril market covered in this report is segmented –
1) By Brand: Prinivil, Zestril, Other Brands
2) By Disease: Hypertension, Heart Failure, Heart Attack
3) By Dosage: Tablet, Liquid
4) By End-Users: Hospitals, Specialty Clinics
Subsegments:
1) By Prinivil: Different Dosage Forms, Generic Versions Of Prinivil
2) By Zestril: Different Dosage Forms, Generic Versions Of Zestril
3) By Other Brands: International Brand Variants, Combination Drug Formulations
Lisinopril Market Leading Players And Competitive Positioning
Major companies operating in the lisinopril market are Merck & Co. Inc., Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Ltd., Cipla Inc., Hikma Pharmaceutical Plc, Apotex Inc., Amneal Pharmaceutical Inc., Lupin Ltd., Zydus Cadila Healthcare Ltd., Hetero Ltd., Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Mylan Pharmaceuticals Inc., Accord Healthcare Ltd., Sandoz International GmbH
View The Full Lisinopril Market Report:
Lisinopril Market Top Region By Revenue And Market Share
North America was the largest region in the lisinopril market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lisinopril market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
